Trials / Recruiting
RecruitingNCT05398003
Medullary Stimulation for the Treatment of Refractory Neck Pain (S2M)
Evaluation of Multimodal Medullary Stimulation in Refractory Neck and Upper Limb Pain
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Nantes University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Number of centres planned : 1 (CHU Nantes) Design : Randomized, Prospective Planning of the study : * Total duration: 34 months * Recruitment period: 24 months. * Follow-up time per patients : 7-10 months Expected number of cases : 12 Treatment, procedure, combination of procedures under consideration : During the study, patients will be implanted with the WAVEWRITER ALPHA™ system with the objective of decreasing patient pain with a spinal cord stimulation mode. There will be a random draw on the order of the stimulation program: * the tonic stimulation "LF": In tonic mode, the electrical stimulation of the sensory fibers of the posterior cords of the spinal cord induces local paresthesias * burst stimulation (or "burst") * high frequency" stimulation (1000 Hz) "High frequency: HF". * combined tonic + burst stimulation * combined tonic + high frequency stimulation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Implantation of the WAVEWRITER ALPHA ™ device | The 12 patients will be implanted by the WAVEWRITER ALPHA ™ device. Then, the order of the three stimulation modes will be randomly selected and will be composed of 5 modalities: * tonic stimulation "LF": In tonic mode, the electrical stimulation of the sensory fibres of the posterior cords of the spinal cord induces local paresthesias * high frequency" stimulation (1000 Hz) "High Frequency". * stimulation in bursts (or "Burst") |
Timeline
- Start date
- 2022-11-23
- Primary completion
- 2026-09-23
- Completion
- 2026-09-23
- First posted
- 2022-05-31
- Last updated
- 2024-11-18
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05398003. Inclusion in this directory is not an endorsement.